Journal
JOURNAL OF OPHTHALMIC INFLAMMATION AND INFECTION
Volume 10, Issue 1, Pages -Publisher
SPRINGER
DOI: 10.1186/s12348-020-00225-z
Keywords
Non-infectious uveitis; Posterior segment of eye; Recurrence; Intravitreal; Corticosteroid; Fluocinolone acetonide; Implant; Microdosing; Macular oedema; Chronic
Categories
Funding
- Alimera Sciences
Ask authors/readers for more resources
Background The current article is a short review of an Alimera Sciences-sponsored symposium held during The 15th International Ocular Inflammation Society Congress in Taiwan on the 14th November 2019 entitled, 'Preventing relapse of non-infectious uveitis effecting the posterior segment of the eye - evaluating the 0.2 mu g/day fluocinolone acetonide intravitreal implant.' Main text The fluocinolone acetonide intravitreal implant was approved in Europe for the prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye and offers a systemic therapy-sparing treatment option by providing low daily dose of corticosteroid into the vitreous for up to 3 years. In the symposium, the presenters reported clinical outcomes from patients with non-infectious uveitis effecting the posterior segment of the eye to support the effectiveness and safety of the implant for up to 3 years in both randomised controlled trials and real-world practices. Conclusions Data showed that over a 36 month period, treatment with the fluocinolone acetonide intravitreal implant was associated with significantly fewer episodes of uveitic recurrence, a significantly longer time to uveitic recurrence, greater improvement in visual acuity, a lower need for adjunctive therapy, and an acceptable safety profile.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available